Form 4: Vera Therapeutics Director, Scott W. Morrison, Acquires 14,000 Stock Options

Director Scott W. Morrison acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025, at an exercise price of $21.19.

Summary

• On May 14, 2025, Scott W. Morrison, a director of Vera Therapeutics, Inc., acquired 14,000 stock options.
• The exercise price of these options is $21.19.
• The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, contingent upon continuous service.
• The options also vest fully upon a change in control, subject to continuous service through that date.
• The expiration date for these options is May 13, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of options by a director is generally viewed as a positive, but it's not a guarantee of future performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to the director's continued service and a potential change in control, suggesting a long-term commitment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes.

Stakeholder Impact

• The acquisition of stock options by a director can influence investor sentiment.

Key Dates

Keywords

stock options, Form 4, director, Vera Therapeutics, VERA, beneficial ownership, insider trading